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Background
PCR-based testing has been widely utilized to assess the
prevalence of Xenotropic Murine Leukemia Virus-related
Virus (XMRV) in prostate cancer and chronic fatigue
syndrome patients. An alternative approach, screening
for antibodies elicited by XMRV infection, represents a
more desirable option for large-scale epidemiologic stu-
dies. In this study, blood donor and retrovirus-infected
populations were screened for serologic evidence of
XMRV infection.
Methods
Plasma from 1000 US blood donors, 100 HIV-1 infected
Cameroonians, 486 HTLV-I infected Japanese, and 156
Japanese HTLV-uninfected controls were screened for
antibodies to XMRV gp70 and p15E using recombinant-
based chemiluminescence immunoassays (CMIAs). CMIA
reactive samples were further evaluated by Western Blot
(WB) and real-time RT-PCR for XMRV pol and env
sequences.
Results
Of US donors, 0.8% (8/1000) were CMIA reactive: 1 p15E
and 3 of 7 gp70 reactive samples WB confirmed yielding
a 0.4% seroreactive rate. No HIV-1 infected specimens
were reactive. Of the Japanese samples, 1/156 uninfected
(0.6%) and 20/486 HTLV-infected samples (4.1%) had
detectable p15E antibodies by CMIA and WB. Eight
additional HTLV-infected samples were gp70 reactive; 4
of 486 (0.8%) were gp70 reactive in WB. No XMRV pol
or env sequences were detected in the seroreactives.
Conclusions
XMRV seroprevalence ranged from 0 - 0.6% in US blood
donors, HIV-1 infected and HTLV uninfected subjects.
Notably, 4.1% of Japanese HTLV-I infected individuals
were p15E reactive. Inspection of sequence homology
between HTLV and XMRV revealed a high level of con-
servation within the immunodominant region of HTLV
gp21 suggesting increased seroreactivity is due to cross-
reactive antibodies.
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